Torrent Pharma Inc C/o, Pharmaceutical Import Profile — United States (DGFT 2022–2026)

Name: Torrent Pharma Inc C/o, Pharmaceutical Import Records from India — 2 Products, $1.1M FOB USD (DGFT 2022–2026)
Creator: TransData Nexus

Suresh Sormare

Explore

Torrent Pharma Inc C/o, — Pharmaceutical Importer Profile (2026) | 2 Products, $1.1M Trade | TransData Nexus

Torrent Pharma Inc C/o,

Pharmaceutical Importer · United States · Cardiovascular Focus · $1.1M Total Trade · DGFT Verified

Torrent Pharma Inc C/o, is a pharmaceutical importer based in United States with a total trade value of $1.1M across 2 products in 2 therapeutic categories. Based on 32 verified import shipments from Indian Customs (DGFT) records, the company actively imports across multiple product segments. Torrent Pharma Inc C/o, sources from 1 verified Indian supplier, with Torrent Pharmaceuticals Limited accounting for 100.0% of imports.

Torrent Pharma Inc C/o, — Import Portfolio & Supplier Network

Torrent Pharma Inc C/o, import network — 2 products from Indian suppliers. Source: Indian Customs (DGFT).

Who Are the Verified Indian Suppliers to Torrent Pharma Inc C/o,?

Customs-verified supplier relationships from Indian DGFT records

Supplier	Value	Shipments	Share
Torrent Pharmaceuticals Limited	$7.6M	304	100.0%

Torrent Pharma Inc C/o, sources from 1 verified Indian supplier across 123 distinct formulations. The sourcing is highly concentrated — Torrent Pharmaceuticals Limited accounts for 100.0% of total imports, indicating a strategic single-source relationship.

What Formulations Does Torrent Pharma Inc C/o, Import?

Formulation	Value	Ships
Isosorbide mononitrate er tablets, USP	$360.9K	14
Pantoprazole sodium dr tablets USP 40 MG	$351.7K	11
Isosorbide mononitrate er tablets, USP	$345.3K	12
Rosuvastatin tablets 20 MG USP (ndc	$319.8K	9
Duloxetine delayed release capsules	$250.7K	13
Sildenafil tablets USP 100MG (ndc	$184.9K	6
Celecoxib capsules 200MG (ndc no.	$152.5K	6
Trazodone hcl tabs USP 300MG (ndc	$150.0K	3
Duloxetine delayed release CAPS USP 20MG	$148.7K	4
Trazodone hcl tabs USP 150MG (ndc	$147.1K	4
Lamotrigine extended release USP 100MG	$143.9K	3
Rosuvastatin tablets 20 MG USP (ndc	$141.1K	3
Nystatin cream USP 100000 un/g, 30g	$139.5K	4
Duloxetine delayed release CAPS USP 60MG	$135.8K	4
Felodipine extended release tablets	$135.0K	9

Import Portfolio — Top 2 by Import Value

#	Product	Category	Value	Ships	Share	Rk
1	Isosorbide	Cardiovascular	$788.3K	26	1.8%	9
2	Dapsone	Antimalarial & Antiparasitic	$300.0K	6	0.9%	3

Torrent Pharma Inc C/o, imports 2 pharmaceutical products across 2 categories into United States totaling $1.1M.

Torrent Pharma Inc C/o, — Corporate Profile & Information

Company type, headquarters, distribution network, and industry role

1Company Overview

Torrent Pharma Inc. is a U.S.-based pharmaceutical importer and distributor specializing in finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. Established in 2004, the company operates as a wholly owned subsidiary of Torrent Pharmaceuticals Ltd., a leading Indian pharmaceutical manufacturer. Headquartered in Basking Ridge, New Jersey, Torrent Pharma Inc. plays a pivotal role in introducing and distributing generic pharmaceutical products within the United States market. The company has successfully commercialized 64 FDA-approved generic products, with several achieving significant market shares in their respective therapeutic categories.

Torrent Pharmaceuticals Ltd., the parent company, is renowned for its extensive portfolio across various therapeutic segments, including cardiovascular, central nervous system, gastrointestinal, and women's healthcare. With a presence in over 50 countries, Torrent Pharma Inc. leverages this global network to source and distribute a diverse range of pharmaceutical products in the U.S.

2Distribution Network

Torrent Pharma Inc. maintains a centralized distribution model from its headquarters in Basking Ridge, New Jersey. This strategic location facilitates efficient logistics and supply chain management, ensuring timely delivery of pharmaceutical products across the United States. The company's distribution network is supported by robust partnerships with third-party logistics providers, enabling it to manage inventory effectively and meet the demands of the U.S. healthcare market. While specific warehouse locations beyond the New Jersey facility are not publicly disclosed, Torrent Pharma Inc.'s operations are designed to optimize distribution efficiency and product availability nationwide.

3Industry Role

In the United States pharmaceutical supply chain, Torrent Pharma Inc. functions primarily as a pharmaceutical importer and distributor. By sourcing finished pharmaceutical formulations from its parent company, Torrent Pharmaceuticals Ltd., and other suppliers, the company ensures a steady supply of generic medications to the U.S. market. Torrent Pharma Inc. collaborates with various stakeholders, including wholesalers, healthcare providers, and pharmacies, to facilitate the distribution of its products. This role is crucial in enhancing access to affordable medications and supporting the overall efficiency of the U.S. pharmaceutical supply chain.

TransData Nexus Research · Company registries, industry databasesMar 2026

Supplier Relationship Intelligence — Torrent Pharma Inc C/o,

Sourcing concentration, supply chain resilience, and strategic implications

1Sourcing Concentration Analysis

Torrent Pharma Inc. exhibits a high degree of supplier concentration, with a total import value of $1.1 million USD from India, comprising 32 shipments of 123 unique formulations. Notably, all imports are sourced from Torrent Pharmaceuticals Ltd., indicating a strategic decision to rely on a single supplier for the majority of its product portfolio. This sourcing strategy may offer benefits such as streamlined logistics, consistent product quality, and favorable pricing terms. However, the lack of diversification introduces potential risks, including supply chain disruptions due to geopolitical events, regulatory changes, or operational challenges within the supplier's facilities. The absence of alternative suppliers could impact Torrent Pharma Inc.'s ability to maintain product availability and meet market demand in such scenarios.

The shipment data reveals a consistent pattern of imports from Torrent Pharmaceuticals Ltd., suggesting a stable and long-term relationship between the two entities. This stability is advantageous for maintaining a reliable supply chain. However, the overreliance on a single supplier underscores the importance of developing contingency plans and exploring opportunities to diversify the supplier base to mitigate potential risks associated with supplier concentration.

2Supply Chain Resilience

Torrent Pharma Inc.'s supply chain resilience is closely tied to the operational stability of Torrent Pharmaceuticals Ltd. The company's reliance on a single supplier for the majority of its product imports means that any disruptions within Torrent Pharmaceuticals Ltd.'s manufacturing facilities could directly affect Torrent Pharma Inc.'s ability to supply products to the U.S. market. While Torrent Pharmaceuticals Ltd. is a reputable manufacturer with a significant global presence, the lack of alternative suppliers introduces vulnerabilities. To enhance supply chain resilience, Torrent Pharma Inc. could consider establishing relationships with additional suppliers, diversifying its product formulations, and developing contingency plans to address potential disruptions. Ensuring that all suppliers comply with FDA regulations and maintain high manufacturing standards is essential for maintaining product quality and regulatory compliance.

Importing Pharmaceuticals into United States — Regulatory Framework

Regulatory authority, GMP requirements, import licensing for United States

1Regulatory Authority & Framework

In the United States, the Food and Drug Administration (FDA) serves as the primary regulatory authority overseeing the importation and distribution of pharmaceutical products. The FDA enforces the Federal Food, Drug, and Cosmetic Act (FD&C Act), which sets forth requirements for the safety, efficacy, and quality of drugs imported into the U.S. Pharmaceutical importers must ensure that their products comply with FDA regulations, including proper labeling, manufacturing practices, and approval status. The FDA's Regulatory Procedures Manual and Investigations Operations Manual provide detailed guidance on import operations and actions.

The FDA's import program aims to protect public health by ensuring that imported drugs meet the same standards as domestically produced drugs. This includes verifying that drugs are not adulterated, misbranded, or unapproved. The FDA examines and analyzes samples of imported drugs to ensure compliance with applicable standards and labeling requirements. Importers are required to file an entry notice and an entry bond with U.S. Customs and Border Protection (CBP), pending a decision regarding the admissibility of the product.

2Import Licensing & GMP

Import licensing requirements for pharmaceutical products entering the United States are governed by the FDA. All foreign drug establishments whose products are imported into the U.S. must register their establishments with the FDA and list all their drug products in commercial distribution in the United States. This registration ensures that the FDA is notified of all regulated products imported into the U.S. Additionally, imported drugs must comply with Good Manufacturing Practice (GMP) regulations, which are enforced by the FDA to ensure that drugs are produced consistently and controlled to quality standards. GMP compliance is essential for maintaining product quality and safety.

Torrent Pharma Inc C/o, — Procurement Pattern Analysis

Product strategy, sourcing profile, and market positioning

1Product Strategy

Torrent Pharma Inc.'s product strategy focuses on importing and distributing generic pharmaceutical formulations, with a particular emphasis on cardiovascular and antimalarial & antiparasitic therapeutic categories. The company's portfolio includes products such as Isosorbide and Dapsone, which are essential in the management of cardiovascular conditions and the treatment of malaria and other parasitic infections. The decision to import these specific therapeutic areas aligns with market demand for affordable and effective generic medications in the United States. By

TransData Nexus Research · DGFT trade data analysisMar 2026

Frequently Asked Questions — Torrent Pharma Inc C/o,

What products does Torrent Pharma Inc C/o, import from India?

Torrent Pharma Inc C/o, imports 2 pharmaceutical products across 2 categories. Top imports: Isosorbide ($788.3K), Dapsone ($300.0K).

Who supplies pharmaceuticals to Torrent Pharma Inc C/o, from India?

Torrent Pharma Inc C/o, sources from 1 verified Indian suppliers. The primary supplier is Torrent Pharmaceuticals Limited (100.0% of imports, $7.6M).

What is Torrent Pharma Inc C/o,'s total pharmaceutical import value?

Torrent Pharma Inc C/o,'s total pharmaceutical import value from India is $1.1M, based on 32 verified shipments in Indian Customs (DGFT) data.

What therapeutic categories does Torrent Pharma Inc C/o, focus on?

Torrent Pharma Inc C/o, imports across 2 categories. The largest: Cardiovascular (72.4%), Antimalarial & Antiparasitic (27.6%).

Get Full Torrent Pharma Inc C/o, Import Intelligence

Access shipment-level details, supplier connections, pricing data, and competitive analysis. TransData Nexus provides verified Indian Customs (DGFT) data trusted by pharmaceutical trade professionals worldwide.

Contact for Data Access Request Live Demo

Official References & Regulatory Resources

Verify import regulations and drug registration requirements with the agencies above.

Research Methodology & Data Transparency

Suresh Sormare

Verified Author

Pharmaceutical Export-Import Analyst & Trade Intelligence Expert

Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.

linkedin.com/in/sureshsormare

Primary Data Source

All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.

Data Source & Methodology

Trade data sourced from Indian Customs (DGFT) export shipment records. Values represent FOB export value in USD. Profile aggregates 2 company name variants from customs records. For current shipment-level data, contact TransData Nexus.